Postdoctoral Research Scientist
Dr Tim Johanssen leads a drug discovery project researching novel combinatorial treatments of glioblastoma in the High Throughput Screening Group at The University of Oxford. His work has generated a concise chemogenomic library along with drug and radiation resistant patient-derived stem cells, which have formed the basis of ongoing large-scale screens in the group.
Tim completed is PhD in neuroscience at the University of Melbourne studying the effects of beta amyloid toxicity in Alzheimer’s disease. Prior to his current position Tim has worked in industry at Eisai London Laboratories and academia at the University of Melbourne before joining the ARUK Oxford Drug Discovery Institute at the University of Oxford.
Throughout his career he has undertaken translation drug discovery research in CNS disorders. His preclinical research has employed in vitro and in vivo models of Alzheimer’s and Parkinson’s diseases with the aim to translate knowledge on the mechanisms underlying these diseases into the design of novel therapeutics and diagnostics.